Infasurf® (calfactant) turns todays into tomorrows by rapidly adsorbing, lowering surface tension, and improving lung compliance overall.

Infasurf® (calfactant) demonstrates surface tension lowering activity equal to that of native lung surfactant.1

In Vitro Studies: Surface Tension Lowering

Redrawn from Wang Z, et al., 1998

Native Lung Surfactant 0.5 mg/mL

Infasurf® (calfactant) 0.75 mg/mL

  • Zero surface tension helps prevent alveoli collapse, increases the ability to achieve equal distribution of air throughout the lung and aids rapid respiratory recovery by increasing lung compliance1,2

Infasurf (calfactant) is biophysically potent2

In Vitro Studies: Concentration Dependent Minimum Surface Tension

Redrawn from Seeger W, et al., 1993

Infasurf® (calfactant)

Curosurf® (poractant alfa)

Survanta® (beractant)

  • At a concentration of 1 mg/mL (circled area), Infasurf® (calfactant) reaches zero surface tension
  • Higher concentrations are required by Curosurf® (poractant alfa) to reach zero surface tension; Survanta® (beractant) never reaches zero surface tension

There are no prospective, randomized clinical trials comparing Infasurf® and Curosurf® with respect to safety or efficacy.

With the first dose, Infasurf® (calfactant) delivers a rapid, sustained response.

Potential for single-dose success and fewer doses.

Lowered FiO2 significantly in the critical first 24 hours

Fraction of Inspired Oxygen (FiO2)

Redrawn from Bloom BT, et al., 1997

Infasurf® (calfactant) n=303

Survanta® (beractant) n=305

*Significant difference (P<0.05) between groups at time indicated.

  • Potential for less oxygen requirement and less days on mechanical ventilation3
  • Infasurf® (calfactant) demonstrates a long duration of action3,4
  • Improvements in FiO2 requirements may not necessarily reduce dosing or predict long-term outcomes
  • Preclinical and biologic testing do not predict clinical effects